Physician profile
William Stephan
NPI 1952370173
$27,398.81
in general payments reported to CMS, 2019-2025
65 companies · $3,282 in 2025
The $3,282 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,305 · 2020: $3,499 · 2021: $4,844 · 2022: $3,991 · 2023: $3,746 · 2024: $3,732 · 2025: $3,282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $89.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,669.60 |
| Education | $89.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,808.31 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $2,244.42 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $1,970.65 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,902.44 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,877.83 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,509.63 | 2019-2025 | Jardiance |
| Pfizer INC. | $1,314.93 | 2019-2025 | |
| Abbott Laboratories | $1,085.77 | 2019-2025 | Freestyle Libre 3, Thoratec Heartmate 3 Lvas Implant Kit, Infinity |
| Merck Sharp & Dohme LLC | $1,008.66 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Astellas Pharma US INC | $889.73 | 2019-2024 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $707.65 | 2019-2023 | Xarelto |
| Amarin Pharma, INC. | $639.68 | 2019-2023 | |
| Bausch Health US, LLC | $594.59 | 2019-2025 | Aplenzin, Wellbutrin |
| Sanofi-Aventis U.S. LLC | $484.49 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $472.77 | 2019-2024 | Trintellix |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Stephan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.